Now I have enough to write a comprehensive preview. Let me pull together key figures and write the markdown report.# Kimberly-Clark (KMB) — Q2 2026 Earnings Preview Report Date: August 4, 2026 (before market open) | Event: 2026Q2 Earnings Call
KMB shares have had a strong run into this report, rallying from an April low near $93 to roughly $114 in early July before settling back to the ~$107-109 range over the past few sessions — still up meaningfully year-to-date. The stock's momentum reflects a combination of steady base-business execution and optimism around the transformative Kenvue acquisition, but it also raises the bar for what the market will consider a "good" quarter.
Consensus expectations: Wall Street is looking for roughly $2.00-$2.01 in adjusted EPS and revenue of approximately $4.22 billion, which would represent EPS growth of about 4% year-over-year. KMB has beaten consensus EPS in each of the last four quarters, so the bar includes an implicit expectation of another beat, but investors will be watching guidance and commentary at least as closely as the headline numbers given the pending Kenvue transaction and rising input-cost noise.
Q1 set the tone for the year and gives useful context for what to expect in Q2:
This is the single biggest swing factor for the quarter. On the Q1 call, CFO Nelson Urdaneta flagged that "in the second quarter... around $50 million stemming from the inflationary impacts that we're seeing as a result of the Middle East war and some of the impacts related to the LA DC fire" would hit the bottom line, expected to be recovered in the second half. He also warned that if oil stays near $100/barrel, the back half could face "gross incremental input costs of around $150 million to $170 million" that are not yet baked into guidance nor offset by mitigation actions. With oil prices remaining elevated on continued Middle East conflict, investors should listen closely for: - Confirmation of the ~$50 million Q2 hit actually materializing as guided. - Updated commentary on second-half mitigation (pricing/RGM, productivity, supplier renegotiation) — management indicated they were "keeping cards close to the vest" pending more clarity. - Whether the long-standing "pricing net of cost" (PNOC) discipline framework, which management says has structurally de-risked the P&L versus the 2022-2023 inflation super-cycle, continues to hold.
Management explicitly guided that Q2 organic growth would step down from Q1's 2.5%, citing "the strongest comp versus 2025, in which for total enterprise last year, we grew about 4%. And in North America volume, it was actually 5%", plus a one-time DC fire headwind. Specifically: - A California distribution center fire is expected to cost North America "around $20 million or 70 to 80 basis points for the North America segment" in net sales. - Management guided that growth should reaccelerate in the second half as these headwinds lap. Confirming this trajectory (rather than a broader deceleration) will be important for the market's read-through to full-year organic growth guidance (framed around ~2.5% category growth).
Q1 saw adjusted gross margin down 60 bps y/y (largely due to lapping the North America private-label diaper exit) but management guided that gross margin and operating profit margin would expand for the balance of the year, "both in the vicinity of 70 to 80 basis points" for the full year. Watch whether Q2 margins show the sequential improvement management promised, especially given the incremental cost pressure discussed above.
The pending ~$48.7 billion acquisition of Kenvue (Tylenol, Listerine, Band-Aid, Neutrogena, etc.) remains the dominant strategic narrative for KMB and likely the focus of analyst Q&A: - Shareholders of both companies overwhelmingly approved the deal on January 29, 2026, with approximately 96% of Kimberly-Clark shares present voting in favor of the stock issuance and about 99% of Kenvue shares voted approving the merger agreement, representing roughly 77% of Kenvue's outstanding shares. - The transaction is expected to close in the second half of 2026, subject to regulatory approvals and customary closing conditions — so investors should look for any update on regulatory/antitrust progress and confirmation of timing. - On the Q1 call, Hsu expressed "even more conviction in the growth potential of the company that we're about to create" after months of joint integration planning, and characterized Kenvue's recent stumbles (notably in North America skin care, oral care, and China) as largely executional rather than structural. - COO Russell Torres detailed early synergy work across more than 40 integration teams spanning logistics (complementary truck-loading economics between K-C's bulky products and Kenvue's dense products), SG&A/systems consolidation, and commercial/e-commerce opportunities. - Related to funding the deal, the IFP (International Family Care and Professional) separation/joint venture with Suzano is expected to close in mid-2026, with proceeds earmarked to help fund the Kenvue cash consideration. KMB now reports IFP as discontinued operations, and full-year adjusted EPS attributable to Kimberly-Clark guidance already reflects the anticipated reduction in income from discontinued operations tied to that closing.
Given the deal's importance, expect commentary on integration milestones, synergy sizing/timing, financing plans (the merger consideration includes roughly 280 million new KMB shares plus ~$6.7 billion of cash), and any regulatory developments since the January shareholder votes.
Management struck a confident tone on demand resilience: "we aren't really seeing any large-scale shifts in consumer buying behavior... our trailing 12-month weighted average category growth is around 2.5%", and noted share gains in "95% of sales weighted markets on share in North America and 84% in international." International strength was notable, with call-outs of double-digit growth in Vietnam and a birth-rate-driven boom in Korea. Watch for continued share/category commentary, particularly given cross-currents from tariffs, regional conflicts (Middle East, and shipping-lane concerns near the Strait of Hormuz), and currency swings (Argentina, Türkiye).
As of Q1, reaffirmed guidance called for: - Organic sales growth in line to ahead of a ~2.5% weighted-average category growth rate. - Adjusted operating profit growth at a mid-to-high single-digit rate on a constant-currency basis. - Adjusted EPS from continuing operations growing at a double-digit rate on a constant-currency basis, aided by roughly 40% growth in equity company income, flat net interest expense, and a ~23% adjusted tax rate. - Adjusted EPS attributable to Kimberly-Clark expected to be roughly flat on a constant-currency basis, reflecting the drag from the IFP deconsolidation, partially offset by ~170 bps of favorable currency translation.
Any change to these targets — especially in light of the oil/input-cost swing factors discussed above — would be a key market-moving item tomorrow.
Going into the print, the debate is less about whether KMB's core "Powering Care" strategy is working (volume/mix trends, innovation-led growth, and share gains all look solid) and more about execution risk on two fronts: (1) whether cost inflation from oil and geopolitical disruption can be offset without denting margins or requiring guidance cuts, and (2) progress toward closing and integrating the transformative Kenvue acquisition, which will reshape KMB into a much larger health-and-wellness company by year-end. A clean beat with reaffirmed guidance and constructive Kenvue/IFP updates would likely be well received given the stock's already-elevated levels; any signs of margin slippage beyond the flagged $50 million Q2 hit, deceleration in underlying volume/mix, or delays/setbacks on the Kenvue timeline would be the primary risks to watch.